What was recalled
This page synthesizes the framework around CoQ10 in commercial pet food. CoQ10 chemistry includes a benzoquinone head group attached to a 10-isoprene-unit lipophilic side chain (in humans and most mammals; some species have different chain lengths). The compound is essential for mitochondrial electron transport between complex I (NADH:ubiquinone oxidoreductase) or complex II (succinate:ubiquinone oxidoreductase) and complex III (ubiquinol:cytochrome c oxidoreductase). It also functions as a lipid-phase antioxidant, regenerating tocopherol (vitamin E) from the tocopheroxyl radical and directly scavenging lipid peroxyl radicals in mitochondrial and other cellular membranes. Tissues with high mitochondrial density and energy demand (cardiac muscle, skeletal muscle, kidney, liver) have correspondingly high tissue CoQ10 content. Our CoQ10 explainer and CoQ10 forms explainer cover the basic nutritional framework.
Commercial pet food CoQ10 supplements use two main forms. Ubiquinone (oxidized CoQ10) is the dominant commercial supplement form by volume, produced by yeast fermentation followed by extraction and crystallization; ubiquinone has high shelf stability and is the historical reference form. Ubiquinol (reduced CoQ10) is more bioavailable but less shelf-stable; ubiquinol must be stabilized in formulation (often with antioxidant complexation or solubilizing oil matrix) to maintain potency through shelf life. The bioavailability advantage of ubiquinol over ubiquinone in human supplementation studies is approximately 3-4x at equivalent oral dose; companion-animal pharmacokinetic data is more limited but qualitatively similar. CoQ10 oral absorption is generally poor regardless of form and is enhanced by co-administration with dietary fat; pet food incorporation in fat-containing matrices is therefore the practical delivery system.
Why it was recalled
The structural controversy has two layers. Layer one — marketing-evidence gap: commercial pet food brands market CoQ10 as a senior cardiac, cognitive, and oral-cavity support ingredient with claims often substantially outrunning the published companion-animal evidence. The human literature is supportive for several clinical contexts (statin-associated myopathy mitigation, heart failure adjunct with NYHA class II-III, mitochondrial disease, certain fertility applications, statin co-management) but the companion-animal data is dominated by extrapolation and limited published controlled trials. Canine trials in heart failure, cognitive aging, and periodontal disease have produced mixed and small effects. Feline data is sparser. The AAFCO ingredient definition for CoQ10 permits inclusion; the regulatory framework does not require efficacy substantiation. The result is that pet owners may pay premium pricing for CoQ10-fortified senior formulations without strong evidence of marketed benefit in their specific pet.
Layer two — ubiquinone versus ubiquinol formulation choice and shelf-life stability: the bioavailability advantage of ubiquinol over ubiquinone is supported in human supplementation studies but the shelf-stability disadvantage requires specialized formulation. Most commercial pet food CoQ10 inclusion uses ubiquinone for shelf stability; the labeled CoQ10 amount may therefore deliver substantially less absorbed CoQ10 than equivalent ubiquinol supplementation. The distinction matters most when CoQ10 inclusion is being relied upon for therapeutic effect (rare in commercial pet food) and less when CoQ10 is included for marketing positioning. Pet owners considering CoQ10 supplementation for cardiac or cognitive indications in senior pets should consider veterinary-supervised stand-alone ubiquinol supplementation rather than relying on commercial pet food maintenance-range inclusion. The broader tocopherol preservation stability controversy framework applies similarly to other fat-soluble antioxidants in pet food formulation.
Health risks for your pet
Clinical CoQ10 deficiency in dogs and cats fed AAFCO-compliant commercial diets is uncommon and rarely diagnosed; CoQ10 measurement in clinical practice is also uncommon. The mechanistic case for supplementation in senior animals with cardiac or cognitive concerns rests on age-associated decline in endogenous synthesis (well-documented in humans, plausibly similar in dogs and cats) plus tissue-level CoQ10 depletion in some disease states. The clinical evidence in companion animals is supportive in mechanism but limited in controlled-trial outcomes; the supplementation is widely considered low-risk in healthy senior animals but the magnitude of benefit beyond placebo is unclear.
CoQ10 excess from dietary sources or supplementation is essentially never seen at typical doses (1-3 mg/kg/day in dogs and cats is well tolerated). Very high doses produce gastrointestinal upset in some animals; chronic very high dosing has not been associated with significant adverse effects in published companion-animal experience. Theoretical interactions with warfarin (CoQ10 has weak anticoagulant-antagonist activity at high doses) warrant caution in pets on anticoagulant therapy. The structural concern at the population level remains marketing-evidence gap rather than safety.
What to do if you bought affected product
Pet owners can manage CoQ10 decisions through several practical approaches: (1) for senior pets with diagnosed cardiac disease, discuss veterinary-supervised CoQ10 supplementation (typically 1-3 mg/kg/day ubiquinol or 3-10 mg/kg/day ubiquinone) with your veterinarian or veterinary cardiologist as an adjunct to standard heart failure management; the evidence base is supportive in mechanism though not definitively validated in companion-animal controlled trials; (2) for senior pets with cognitive aging signs, discuss supplementation as part of a broader cognitive-support framework that may include diet change to commercial senior cognitive support formulations (Hill’s b/d, Purina Bright Mind, others), structured environmental enrichment, and MCT oil supplementation (see our MCT oil controversy overview); (3) for healthy adult and young dogs and cats, CoQ10 supplementation has no clear maintenance indication; endogenous synthesis is typically adequate; (4) do not pay premium pricing for CoQ10-fortified maintenance diets without specific veterinary indication — the commercial pet food inclusion typically delivers maintenance-range dosing well below therapeutic-range supplementation; (5) for ubiquinol versus ubiquinone selection, ubiquinol is the more bioavailable form when stand-alone supplementation is indicated; commercial pet food CoQ10 inclusion typically uses ubiquinone for shelf-stability reasons; (6) verify with your veterinarian if your pet is on warfarin or other anticoagulant therapy — CoQ10 has weak anticoagulant-antagonist activity at high doses.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 awards modest scoring credit for documented CoQ10 inclusion in senior commercial pet food formulations per our published methodology, recognizing manufacturer attention to age-associated mitochondrial and antioxidant support. The rubric does not weight dose adequacy versus therapeutic range, since pet food CoQ10 inclusion universally provides maintenance-range dosing below the therapeutic threshold required for clinical cardiac or cognitive indications. Pet owners optimizing for senior wellness should treat scoring credit as a tiebreaker between adequate base formulations and should pursue veterinary-supervised therapeutic supplementation when clinical indication is present. The structural marketing-evidence gap remains the dominant feature of the category.